3-(4-氟苯氧基)苯甲醛 | 65295-61-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-氟苯氧基)苯甲醛
• 英文名称: 3-(4-fluorophenoxy)benzaldehyde
• 英文别名: 3-(4-fluorophenyloxy)-benzaldehyde
• CAS: 65295-61-6
• 化学式: C₁₃H₉FO₂
• 分子量: 216.212
• InChiKey: HTBZPEDBMOXWID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2913000090

反应信息

• 作为反应物：
  描述：

  3-(4-氟苯氧基)苯甲醛 在 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以94%的产率得到(E)-3-(4-fluorophenoxy)benzaldehyde oxime
  参考文献：
  名称：

  [EN] HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS
  [FR] HYDROXYPHÉNYLSULFONAMIDES COMME INHIBITEURS DE BCL ANTIAPOPTOTIQUES

  摘要：

  本发明提供了化合物的结构式(I)：或其立体异构体、互变异构体、盐或溶剂合物，其中变量在此处定义。式(I)化合物是Bcl-2家族抗凋亡蛋白的抑制剂，含有该化合物的组合物以及使用该化合物治疗疾病的方法。

  公开号：

  WO2009152082A1
• 作为产物：
  描述：

  1-氯-4-氟苯 在 1,3-二甲基-2-咪唑啉酮 、 manganese(IV) oxide 、 8-羟基喹啉 、 potassium carbonate 、 copper(l) chloride 作用下， 以 氯仿 为溶剂， 反应 75.5h， 生成 3-(4-氟苯氧基)苯甲醛
  参考文献：
  名称：

  Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase. 3. Discovery of a Novel Series of N-Alkyl-N-[(fluorophenoxy)benzyl]-N‘-arylureas with Weak Toxicological Effects on Adrenal Glands

  摘要：

  A series of N-alkyl-N-[(fluorophenoxy)benzyl] -N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O-acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'-aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.

  DOI：

  10.1021/jm980399q

文献信息

• Potent inhibition of Norwalk virus by cyclic sulfamide derivatives
  作者：Dengfeng Dou、Kok-Chuan Tiew、Guijia He、Sivakoteswara Rao Mandadapu、Sridhar Aravapalli、Kevin R. Alliston、Yunjeong Kim、Kyeong-Ok Chang、William C. Groutas

  DOI：10.1016/j.bmc.2011.08.054

  日期：2011.10

  A new class of compounds that exhibit anti-norovirus activity in a cell-based system and embody in their structure a cyclosulfamide scaffold has been identified. The structure of the initial hit (compound 2a, ED50 4 μM, TD50 50 μM) has been prospected by exploiting multiple points of diversity and generating appropriate structure–activity relationships.

  已鉴定出一类在基于细胞的系统中表现出抗诺如病毒活性并在其结构中包含环磺酰胺支架的新化合物。初始命中的结构（化合物2a，ED 50 4 μM，TD 50 50 μM）已通过利用多个多样性点并生成适当的结构-活性关系进行了展望。
• Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure
  作者：Zhongpeng Ding、Mingxu Ma、Changjiang Zhong、Shixiao Wang、Zhangyu Fu、Yingwei Hou、Yuqian Liu、Lili Zhong、Yanyan Chu、Feng Li、Cai Song、Yuxi Wang、Jinliang Yang、Wenbao Li

  DOI：10.1016/j.bmc.2019.115186

  日期：2020.1

  The co-crystal structure of Compound 6b with tubulin was prepared and solved for indicating the binding mode and for further optimization. Based on the co-crystal structures of tubulin with plinabulin and Compound 6b, a total of 27 novel A/B/C-rings plinabulin derivatives were designed and synthesized. Their biological activities were evaluated against human lung cancer NCI-H460 cell line. The optimum

  制备化合物6b与微管蛋白的共晶体结构，并对其进行解析以表明结合模式并进一步优化。基于微管蛋白与纤连蛋白和化合物6b的共晶体结构，总共设计和合成了27种新颖的A / B / C环纤连蛋白衍生物。评估其针对人肺癌NCI-H460细胞系的生物学活性。通过对三个系列衍生物的SAR研究，最佳的苯氧基-二酮哌嗪型化合物6o表现出高强的细胞毒性（IC50 = 4.0 nM），其比匹林布林（IC50 = 26.2 nM）更有效，并且与化合物6b（IC50 = 3.8 nM）相似）对抗人肺癌NCI-H460细胞系。随后，针对其他四种人类癌细胞系评估了化合物6o。微管蛋白聚合测定和免疫荧光测定均表明化合物6o可有效抑制微管聚合。此外，阐明了这些纤连蛋白衍生物的物理性质和分子对接的理论计算。基于分子对接的结果，化合物6o的结合模式类似于化合物6b。理论计算的化合物6o的LogPo / w和PCaco优于化合物6
• Novel cyclopropane carboxylic acid derivatives
  申请人：Roussel Uclaf

  公开号：US04833163A1

  公开（公告）日：1989-05-23

  Novel isomers and mixtures thereof of cyclopropane carboxylic acid derivatives with a 3-unsaturated side chain of Z geometry of the formula ##STR1## wherein A' is ##STR2## wherein R.sub.13 is selected from the group consisting of hydrogen and CN and R is an optionally unsaturated alkyl of 1 to 18 carbon atoms having insecticidal and nematocidal activity as well as plant and animal acaricidal activity and their preparation.

  环丙烷羧酸衍生物的新异构体及其混合物，具有Z几何构型的3-不饱和侧链，其通式如上所示，其中A'为如上所示的结构，其中R13选自氢和氰基，R为1至18个碳原子的可选不饱和烷基，具有杀虫、杀线虫、植物和动物杀螨活性及其制备方法。
• Probing the Hydrophobic Binding Pocket of G-Protein-Coupled Lysophosphatidylserine Receptor GPR34/LPS₁ by Docking-Aided Structure–Activity Analysis
  作者：Misa Sayama、Asuka Inoue、Sho Nakamura、Sejin Jung、Masaya Ikubo、Yuko Otani、Akiharu Uwamizu、Takayuki Kishi、Kumiko Makide、Junken Aoki、Takatsugu Hirokawa、Tomohiko Ohwada

  DOI：10.1021/acs.jmedchem.7b00693

  日期：2017.7.27

  relationship of ligands of GPR34, one of the LysoPS receptor subtypes, focusing on recognition of the long-chain fatty acid moiety by the hydrophobic pocket. By introducing benzene ring(s) into the fatty acid moiety of 2-deoxy-LysoPS, we explored the binding site’s preference for the hydrophobic shape. A tribenzene-containing fatty acid surrogate with modifications of the terminal aromatic moiety showed potent

  某些G蛋白偶联受体（GPCR）的配体已被鉴定为内源性脂质，例如溶血磷脂酰丝氨酸（LysoPS）。在这里，我们分析了LysoPS受体亚型之一的GPR34配体的结构-活性关系的分子基础，重点是疏水口袋对长链脂肪酸部分的识别。通过将苯环引入2-脱氧的脂肪酸部分-LysoPS，我们探索了结合位点对疏水形状的偏好。具有末端芳族部分的修饰的含三苯的脂肪酸替代物显示出对GPR34的有效激动活性。这些衍生物与基于GPR34的同源性建模/基于分子动力学的虚拟结合位点的计算对接表明，基于苯的脂质替代物中的纽结与GPR34的L形疏水口袋相匹配。在末端苯环的4-位带有庞大的叔丁基的基于四苯的脂质类似物表现出强效的GPR34激动活性，证实了本发明的疏水结合口袋模型。
• Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors
  申请人：——

  公开号：US20020173665A1

  公开（公告）日：2002-11-21

  Compounds of formula (I) 1 are novel P2X 3 and P2X 2 /P2X 3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.

  化合物的式(I)1是新颖的P2X3和P2X2/P2X3拮抗剂，可用于治疗疼痛、尿失禁和膀胱过度活动。